bluebird bio (BLUE) Competitors $0.47 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BLUE vs. ALVR, TIL, KOD, CABA, BDTX, CADL, ADVM, SCLX, CRBU, and CGENShould you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include AlloVir (ALVR), Instil Bio (TIL), Kodiak Sciences (KOD), Cabaletta Bio (CABA), Black Diamond Therapeutics (BDTX), Candel Therapeutics (CADL), Adverum Biotechnologies (ADVM), Scilex (SCLX), Caribou Biosciences (CRBU), and Compugen (CGEN). These companies are all part of the "biological products, except diagnostic" industry. bluebird bio vs. AlloVir Instil Bio Kodiak Sciences Cabaletta Bio Black Diamond Therapeutics Candel Therapeutics Adverum Biotechnologies Scilex Caribou Biosciences Compugen AlloVir (NASDAQ:ALVR) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership. Do analysts recommend ALVR or BLUE? bluebird bio has a consensus target price of $4.63, indicating a potential upside of 894.28%. Given bluebird bio's stronger consensus rating and higher possible upside, analysts plainly believe bluebird bio is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60bluebird bio 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders & institutionals have more ownership in ALVR or BLUE? 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 33.9% of AlloVir shares are owned by company insiders. Comparatively, 1.4% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, ALVR or BLUE? AlloVir has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Which has preferable valuation and earnings, ALVR or BLUE? AlloVir has higher earnings, but lower revenue than bluebird bio. AlloVir is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$1.23-0.78bluebird bio$54.90M1.65-$211.91M-$2.22-0.21 Does the MarketBeat Community favor ALVR or BLUE? bluebird bio received 1011 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 71.39% of users gave bluebird bio an outperform vote while only 57.45% of users gave AlloVir an outperform vote. CompanyUnderperformOutperformAlloVirOutperform Votes2757.45% Underperform Votes2042.55% bluebird bioOutperform Votes103871.39% Underperform Votes41628.61% Is ALVR or BLUE more profitable? AlloVir has a net margin of 0.00% compared to bluebird bio's net margin of -567.29%. AlloVir's return on equity of -89.62% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -89.62% -73.01% bluebird bio -567.29%-207.25%-51.70% Does the media prefer ALVR or BLUE? In the previous week, bluebird bio had 1 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for bluebird bio and 2 mentions for AlloVir. AlloVir's average media sentiment score of 1.31 beat bluebird bio's score of 0.42 indicating that AlloVir is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AlloVir 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive bluebird bio 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summarybluebird bio beats AlloVir on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLUE vs. The Competition Export to ExcelMetricbluebird bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.36M$3.16B$5.40B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-0.2112.18115.5615.18Price / Sales1.65332.351,484.3492.77Price / CashN/A148.6339.6634.07Price / Book0.264.024.665.02Net Income-$211.91M-$42.25M$119.06M$225.46M7 Day Performance-2.96%8.06%0.80%0.37%1 Month Performance-4.35%8.71%5.65%3.57%1 Year Performance-84.72%32.10%36.76%29.44% bluebird bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLUEbluebird bio2.8541 of 5 stars$0.47flat$4.63+894.3%-84.1%$90.36M$54.90M-0.21323Upcoming EarningsAnalyst ForecastALVRAlloVir2.5674 of 5 stars$0.80+1.3%N/A-38.1%$92.35MN/A-0.65110Upcoming EarningsShort Interest ↓News CoveragePositive NewsTILInstil Bio3.1455 of 5 stars$31.06+0.6%$110.00+254.2%+293.2%$202.01MN/A-1.6949Gap DownKODKodiak Sciences4.5694 of 5 stars$3.74+9.0%$5.00+33.7%+149.4%$196.48MN/A-0.9990Positive NewsCABACabaletta Bio2.4755 of 5 stars$3.91+1.6%$28.10+618.7%-74.8%$188.76MN/A-2.0650BDTXBlack Diamond Therapeutics2.2329 of 5 stars$2.98-2.0%$15.50+420.1%+56.6%$167.63MN/A-1.9990Upcoming EarningsShort Interest ↑CADLCandel Therapeutics1.5488 of 5 stars$5.60+1.4%$11.00+96.4%+486.7%$166.63M$120,000.00-3.3160Negative NewsADVMAdverum Biotechnologies3.8273 of 5 stars$7.98-1.2%$28.17+253.0%-18.8%$165.64M$3.60M-1.00190Short Interest ↑SCLXScilex2.8666 of 5 stars$0.86-3.4%$11.33+1,215.7%-46.3%$165.21M$46.74M-0.6080CRBUCaribou Biosciences2.1193 of 5 stars$1.77-2.7%$11.25+535.6%-38.3%$159.86M$33.11M-1.27100Upcoming EarningsCGENCompugen2.1732 of 5 stars$1.70-1.2%$4.00+135.3%+125.0%$151.71M$42.72M-17.0068Positive News Related Companies and Tools Related Companies AlloVir Competitors Instil Bio Competitors Kodiak Sciences Competitors Cabaletta Bio Competitors Black Diamond Therapeutics Competitors Candel Therapeutics Competitors Adverum Biotechnologies Competitors Scilex Competitors Caribou Biosciences Competitors Compugen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLUE) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
